OSE Immunotherapeutics SA (EPA: OSE)

Market Cap	188.17M
Revenue (ttm)	83.44M
Net Income (ttm)	46.03M
Shares Out	21.75M
EPS (ttm)	2.01
PE Ratio	4.29
Forward PE	2.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	135,084
Open	9.22
Previous Close	9.07
Day's Range	8.65 - 9.22
52-Week Range	3.12 - 11.58
Beta	0.90
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 27, 2024

About OSE Immunotherapeutics

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 55
• Stock Exchange: Euronext Paris
• Ticker Symbol: OSE

Financial Performance

In 2023, OSE Immunotherapeutics's revenue was 2.23 million, a decrease of -87.83% compared to the previous year's 18.30 million. Losses were -23.00 million, 29.5% more than in 2022.